Endocrinology Frontiers

[{"query":"Frontiers in Endocrinology","message_files":[{"filename":"temp8729590845987664198_虚拟基础文章案例2 Frontiers in Endocrinology.docx","type":"document","url":"https://ai.medsci.cn/dev-api/admin-api/infra/file/4/get/3a6bb55252e13dccaf006b5100c8784d313627e69f342c3a758d448f7995747a.docx","size":24550}],"answer":"\n\n提炼待评估文件信息：\n\n标题： \nResveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress \n\n摘要： \n该研究探讨了白藜芦醇对多囊卵巢综合征（PCOS）小鼠模型的治疗效果，重点研究其对卵巢线粒体功能和氧化应激的调节机制。通过建立高脂饮食和来曲唑诱导的PCOS小鼠模型，研究发现白藜芦醇显著改善了小鼠的体重、葡萄糖耐受性、胰岛素敏感性以及卵巢功能。进一步分析表明，白藜芦醇通过激活SIRT1/PGC-1α轴和AMPK/mTOR信号通路，增强线粒体生物发生和功能，同时减少氧化应激，从而改善PCOS相关病理特征。\n\n关键词： \nresveratrol, polycystic ovary syndrome, mitochondrial dysfunction, oxidative stress, SIRT1, PGC-1α, AMPK/mTOR \n\n主要章节： \n1. Introduction \n2. Materials and methods \n - 实验动物 \n - 主要试剂和仪器 \n - PCOS小鼠模型的建立与治疗 \n - 阴道涂片检测发情周期 \n - 葡萄糖耐受试验（OGTT）和胰岛素耐受试验（ITT） \n - Western blot和基因表达分析 \n3. Results \n - 白藜芦醇改善PCOS小鼠的肥胖、葡萄糖耐受性和胰岛素抵抗 \n - 白藜芦醇改善PCOS小鼠的卵巢功能和形态 \n - 白藜芦醇促进SIRT1和PGC-1α表达并增强抗氧化能力 \n - 白藜芦醇激活AMPK/mTOR信号通路 \n4. Discussion \n\n预期目标： \n该研究旨在通过Frontiers in Endocrinology期刊发表，目标是展示白藜芦醇在改善PCOS病理特征中的潜在治疗作用及其机制。\n\n综上所述，需求分类为“文章审稿”。\n\n请您确认以上信息是否正确，已默认按照上述需求执行，若需求匹配不对，请中止流程，并补充提交具体的需求。\n\n分类科学家判断您的研究类型为：转化医学研究\n\n转化医学研究专家正在审核~\n\n### 思考评估过程\n\n#### 1. 研究背景与目的\n- 背景：该研究探讨了白藜芦醇（Resveratrol）对多囊卵巢综合征（PCOS）小鼠模型的治疗效果，特别是其对卵巢线粒体功能和氧化应激的调节机制。\n- 目的：通过建立PCOS小鼠模型，研究白藜芦醇对卵巢功能的影响及其机制，包括改善代谢紊乱和减轻卵巢损伤。\n\n#### 2. 材料与方法\n- 实验动物：使用C57BL/6J雌性小鼠，年龄为4-5周，体重20±2g。\n- 主要试剂和仪器：高脂饲料、来曲唑、白藜芦醇等。\n- PCOS小鼠模型的建立与治疗：小鼠接受来曲唑和高脂饮食诱导PCOS模型，然后随机分为PCOS组和白藜芦醇治疗组。\n- 阴道涂片检测发情周期：通过阴道涂片检测小鼠的发情周期。\n- 葡萄糖耐受试验（OGTT）和胰岛素耐受试验（ITT）：监测小鼠的血糖和胰岛素耐受性。\n- Western blot和基因表达分析：使用Western blot和qPCR检测卵巢组织中关键蛋白（如SIRT1、PGC-1α、SOD2）和AMPK/mTOR信号通路的变化。\n\n#### 3. 结果\n- 白藜芦醇改善PCOS小鼠的肥胖、葡萄糖耐受性和胰岛素抵抗：治疗后，PCOS小鼠的体重显著下降，葡萄糖耐受性和胰岛素敏感性得到改善。\n- 白藜芦醇改善PCOS小鼠的卵巢功能和形态：治疗后，卵巢结构得到改善，囊状卵泡数量减少，卵泡发育恢复正常。\n- 白藜芦醇促进SIRT1和PGC-1α表达并增强抗氧化能力：治疗后，SIRT1和PGC-1α的表达水平显著提高，SOD2的表达也增加。\n- 白藜芦醇激活AMPK/mTOR信号通路：治疗后，AMPK的磷酸化水平增加，mTOR的磷酸化水平降低。\n\n#### 4. 讨论\n- PCOS的复杂性：PCOS是一种复杂的内分泌和代谢疾病，卵巢功能障碍与全身代谢健康密切相关。\n- 白藜芦醇的作用机制：研究表明，白藜芦醇通过激活SIRT1/PGC-1α轴和AMPK/mTOR信号通路，改善了PCOS相关的病理特征，包括减轻卵巢线粒体功能障碍和氧化应激。\n\n#### 5. 数据可用性声明\n- 所有原始数据包含在文章或补充材料中。\n\n#### 6. 伦理声明\n- 动物实验得到了全球医学院实验动物福利伦理委员会的批准。\n\n#### 7. 作者贡献\n- 各位作者在数据获取、分析与解释、手稿撰写等方面均做出了贡献。\n\n#### 8. 资金来源\n- 该研究得到了国家自然科学基金（82100888, 31960333, 81960555）、上海市自然科学基金（2022AAC03033）和上海市重点研发项目（2021BFG01020）的支持。\n\n#### 9. 竞争利益声明\n- 作者声明没有商业或财务利益冲突。\n\n#### 10. 发表期刊\n- 该研究计划通过《内分泌学前沿》（Frontiers in Endocrinology）期刊发表。\n\n### 匹配评估\n该研究符合转化医学研究的要求，因为它：\n- 涉及临床前动物模型：使用C57BL/6J雌性小鼠建立了PCOS模型，这有助于理解疾病的机制。\n- 探讨了药物的治疗效果：研究了白藜芦醇对PCOS小鼠模型的治疗效果，包括改善代谢紊乱和卵巢功能。\n- 详细描述了实验设计和方法：提供了详细的实验动物选择、模型建立、治疗方法和检测手段。\n- 结果明确：通过多种检测手段（如Western blot、基因表达分析、生化检测等）验证了白藜芦醇的效果。\n- 讨论了机制：深入探讨了白藜芦醇可能通过SIRT1/PGC-1α和AMPK/mTOR信号通路改善PCOS的机制。\n- 具有临床应用前景：研究结果为白藜芦醇作为PCOS治疗药物的应用提供了新的视角。\n\n### 需求匹配总结\n该研究完全符合“文章审稿”的需求，因为它详细描述了研究背景、目的、实验设计、结果和讨论，并且提供了充分的数据支持和机制解释。因此，可以继续进行审稿流程。\n\n### 审稿建议\n1. 研究背景：确保背景信息准确且全面，涵盖PCOS的流行病学和病理生理学。\n2. 实验设计：确认实验设计合理，对照组和实验组的设置清晰。\n3. 结果部分：检查结果图和表是否清晰、准确，数据是否充分支持结论。\n4. 讨论部分：评估讨论部分是否合理解释了研究结果，并提出了合理的假设和未来研究方向。\n5. 文献引用：确保所有引用的文献都是最新的且相关性高。\n6. 伦理声明：确认伦理声明符合相关法规和标准。\n7. 资金来源：确认资金来源的披露是否完整且透明。\n\n综上所述，该研究符合转化医学研究的要求，可以继续进行审稿流程。\n \n\n\n\nBased on the novelty search, this manuscript does not appear to be a previously published article. The following review is based on the assumption that this is a new submission.\n\n***\n\nReviewer Report\n\nManuscript ID: [Internal Use]\nManuscript Title: Resveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress\nTarget Journal: Frontiers in Endocrinology\nDate: 2025-08-01\n\n### Stage 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Frontiers in Endocrinology\n\nRecent articles in Frontiers in Endocrinology on PCOS and natural compounds often share these characteristics:\n* Model System: Use of established animal models (e.g., letrozole, DHEA, or high-fat diet-induced) is common.\n* Scope: Studies typically combine systemic metabolic phenotyping (e.g., body weight, glucose/insulin tolerance) with organ-specific analysis (ovarian histology, hormone profiles).\n* Mechanism: A clear focus on a specific molecular pathway is expected. Studies investigating mitochondrial function, oxidative stress, and inflammation are frequently published.\n* Methods: Standard molecular biology techniques such as Western blot, qPCR, and immunohistochemistry/immunofluorescence are the norm. More advanced techniques like Seahorse analysis for mitochondrial respiration or direct ROS measurements are valued but not always required.\n\n2. Journal Preferences and Requirements\n\n* Reviewer Preference: The journal favors methodologically sound research that provides a clear, albeit sometimes incremental, advance in the field. The study must be well-controlled and the conclusions must be directly supported by the data presented.\n* Innovation Requirement: Groundbreaking novelty is not a strict prerequisite. Studies that validate a known mechanism in a new context (e.g., resveratrol's known effects on SIRT1/AMPK applied to PCOS ovaries) or provide a more detailed mechanistic link for a previously observed phenomenon are suitable. The current manuscript fits this profile.\n* Research Depth Requirement: The journal expects a complete story at the level of investigation. For an in vivo study, this means robust phenotyping correlated with molecular changes in the target tissue. While this study provides this, it lacks direct functional assays of mitochondrial health (e.g., ATP production, ROS levels, membrane potential), which would strengthen the claims significantly.\n\n3. Assessment based on BMJ Reviewer Guidelines\n\n* Importance & Originality: The topic is of high clinical relevance, as PCOS is a common disorder with significant metabolic and reproductive consequences. The focus on mitochondrial dysfunction as a therapeutic target is current and important. The originality is moderate; the therapeutic effects of resveratrol and its link to the SIRT1/AMPK pathway are known in other metabolic contexts. The contribution here is the specific application and validation within a PCOS ovarian model.\n* Study Design & Methodology: The study design contains a significant flaw that undermines the conclusions. The methods section lacks precision in several areas. The sample size (n=6) is minimal for animal research.\n* Ethics & Transparency: The manuscript includes an ethics approval statement, a data availability statement, and author contributions, which meets the journal's transparency standards.\n\n### Stage 2: Overall Review\n\n1. Journal Fit Analysis\n\nThe manuscript's topic, experimental approach, and scope are well-aligned with the 'Reproductive Endocrinology' or 'Experimental Endocrinology' sections of Frontiers in Endocrinology. The level of data presented is generally consistent with the journal's publication standards, provided the methodological issues are addressed.\n\n2. Innovation Assessment\n\nThe study is not highly innovative but serves as a confirmatory and mechanistic investigation. It connects several established concepts: resveratrol's therapeutic potential, the role of mitochondrial dysfunction in PCOS, and the SIRT1/PGC-1α/AMPK signaling axis. Its value lies in providing direct in vivo evidence that these elements are interconnected in the context of PCOS pathology in the ovary.\n\n3. Research Value Assessment\n\nThe findings have potential translational value by supporting the use of resveratrol as a therapeutic agent for PCOS. The study provides a plausible biological mechanism, which is valuable for guiding future research and potential clinical applications. It reinforces the idea that targeting mitochondrial health is a viable strategy for managing PCOS.\n\n4. Methodology Assessment\n\nThe methodology is the primary weakness of this manuscript.\n* Critical Flaw: The experimental design described in section 2.4 is unclear and potentially invalid. It states the PCOS group received a high-fat diet and letrozole, while the resveratrol group received resveratrol. It fails to specify if the resveratrol group also received the high-fat diet and letrozole. If the resveratrol group did not receive letrozole, the comparison against the PCOS group is meaningless, as any observed improvement could be due to the withdrawal of the disease-inducing agent rather than the therapeutic action of resveratrol. This must be clarified. If the design is as written, the results are uninterpretable.\n* Lack of Direct Functional Evidence: The conclusions about improving mitochondrial function are based solely on the expression of upstream regulators (SIRT1, PGC-1α) and an antioxidant enzyme (SOD2). There are no direct measurements of mitochondrial biogenesis (e.g., mtDNA copy number), function (e.g., ATP levels, Seahorse analysis), or oxidative stress (e.g., ROS levels, lipid peroxidation assays). The link is correlational, not causal.\n* Insufficient Detail: The methods section lacks specificity. For example, "NDA/RNA/Protein Kit" and "Western blot reagent" are not informative. The specific post-hoc test used after ANOVA is not mentioned.\n* Small Sample Size: An n of 6 per group is low and may not provide sufficient statistical power, increasing the risk of a Type II error.\n\n5. Overall Recommendation: Major Revision\n\nThis manuscript addresses an important topic and presents a coherent hypothesis. The data on systemic metabolism and ovarian morphology are clear. However, the potential critical flaw in the experimental design of the treatment groups must be addressed. Without this clarification, the core conclusion of the paper is not supported. Furthermore, to substantiate the claims about mitochondrial function, the authors should ideally provide more direct functional data.\n\nTherefore, the manuscript requires Major Revision before it can be considered for publication. The authors must:\n1. Unequivocally clarify the experimental design for all groups during the treatment phase. If the design was flawed, the work may need to be repeated.\n2. Strengthen the mechanistic claims by adding direct functional assays for mitochondrial health and oxidative stress, or significantly tone down the conclusions to reflect the correlational nature of the current data.\n3. Revise the methods section to include precise details of all kits, reagents, and statistical tests.\n\n【--Final content--】\n\n\n 好的，我将基于您提供的《待审稿文章全文》和《第一阶段和第二阶段的评审结果》，以《Frontiers in Endocrinology》期刊审稿人的身份，完成一份详细的审稿报告。\n\n***\n\n### Reviewer Report\n\nManuscript ID: [Internal Use]\nManuscript Title: Resveratrol ameliorates polycystic ovary syndrome in mice by mitigating ovarian mitochondrial dysfunction and oxidative stress\nTarget Journal: Frontiers in Endocrinology\nDate: 2025-08-01\n\n### Stage 1: Target Journal Analysis\n\n1. Analysis of Similar Articles in Frontiers in Endocrinology\n\nRecent articles in Frontiers in Endocrinology on PCOS and natural compounds often share these characteristics:\n* Model System: Use of established animal models (e.g., letrozole, DHEA, or high-fat diet-induced) is common.\n* Scope: Studies typically combine systemic metabolic phenotyping (e.g., body weight, glucose/insulin tolerance) with organ-specific analysis (ovarian histology, hormone profiles).\n* Mechanism: A clear focus on a specific molecular pathway is expected. Studies investigating mitochondrial function, oxidative stress, and inflammation are frequently published.\n* Methods: Standard molecular biology techniques such as Western blot, qPCR, and immunohistochemistry/immunofluorescence are the norm. More advanced techniques like Seahorse analysis for mitochondrial respiration or direct ROS measurements are valued but not always required.\n\n2. Journal Preferences and Requirements\n\n* Reviewer Preference: The journal favors methodologically sound research that provides a clear, albeit sometimes incremental, advance in the field. The study must be well-controlled and the conclusions must be directly supported by the data presented.\n* Innovation Requirement: Groundbreaking novelty is not a strict prerequisite. Studies that validate a known mechanism in a new context (e.g., resveratrol's known effects on SIRT1/AMPK applied to PCOS ovaries) or provide a more detailed mechanistic link for a previously observed phenomenon are suitable. The current manuscript fits this profile.\n* Research Depth Requirement: The journal expects a complete story at the level of investigation. For an in vivo study, this means robust phenotyping correlated with molecular changes in the target tissue. While this study provides this, it lacks direct functional assays of mitochondrial health (e.g., ATP production, ROS levels, membrane potential), which would strengthen the claims significantly.\n\n3. Assessment based on BMJ Reviewer Guidelines\n\n* Importance & Originality: The topic is of high clinical relevance, as PCOS is a common disorder with significant metabolic and reproductive consequences. The focus on mitochondrial dysfunction as a therapeutic target is current and important. The originality is moderate; the therapeutic effects of resveratrol and its link to the SIRT1/AMPK pathway are known in other metabolic contexts. The contribution here is the specific application and validation within a PCOS ovarian model.\n* Study Design & Methodology: The study design contains a significant flaw that undermines the conclusions. The methods section lacks precision in several areas. The sample size (n=6) is minimal for animal research.\n* Ethics & Transparency: The manuscript includes an ethics approval statement, a data availability statement, and author contributions, which meets the journal's transparency standards.\n\n### Stage 2: Overall Review\n\n1. Journal Fit Analysis\n\nThe manuscript's topic, experimental approach, and scope are well-aligned with the 'Reproductive Endocrinology' or 'Experimental Endocrinology' sections of Frontiers in Endocrinology. The level of data presented is generally consistent with the journal's publication standards, provided the methodological issues are addressed.\n\n2. Innovation Assessment\n\nThe study is not highly innovative but serves as a confirmatory and mechanistic investigation. It connects several established concepts: resveratrol's therapeutic potential, the role of mitochondrial dysfunction in PCOS, and the SIRT1/PGC-1α/AMPK signaling axis. Its value lies in providing direct in vivo evidence that these elements are interconnected in the context of PCOS pathology in the ovary.\n\n3. Research Value Assessment\n\nThe findings have potential translational value by supporting the use of resveratrol as a therapeutic agent for PCOS. The study provides a plausible biological mechanism, which is valuable for guiding future research and potential clinical applications. It reinforces the idea that targeting mitochondrial health is a viable strategy for managing PCOS.\n\n4. Methodology Assessment\n\nThe methodology is the primary weakness of this manuscript.\n* Critical Flaw: The experimental design described in section 2.4 is unclear and potentially invalid. It states the PCOS group received a high-fat diet and letrozole, while the resveratrol group received resveratrol. It fails to specify if the resveratrol group also received the high-fat diet and letrozole. If the resveratrol group did not receive letrozole, the comparison against the PCOS group is meaningless, as any observed improvement could be due to the withdrawal of the disease-inducing agent rather than the therapeutic action of resveratrol. This must be clarified. If the design is as written, the results are uninterpretable.\n* Lack of Direct Functional Evidence: The conclusions about improving mitochondrial function are based solely on the expression of upstream regulators (SIRT1, PGC-1α) and an antioxidant enzyme (SOD2). There are no direct measurements of mitochondrial biogenesis (e.g., mtDNA copy number), function (e.g., ATP levels, Seahorse analysis), or oxidative stress (e.g., ROS levels, lipid peroxidation assays). The link is correlational, not causal.\n* Insufficient Detail: The methods section lacks specificity. For example, "NDA/RNA/Protein Kit" and "Western blot reagent" are not informative. The specific post-hoc test used after ANOVA is not mentioned.\n* Small Sample Size: An n of 6 per group is low and may not provide sufficient statistical power, increasing the risk of a Type II error.\n\n5. Overall Recommendation: Major Revision\n\nThis manuscript addresses an important topic and presents a coherent hypothesis. The data on systemic metabolism and ovarian morphology are clear. However, the potential critical flaw in the experimental design of the treatment groups must be addressed. Without this clarification, the core conclusion of the paper is not supported. Furthermore, to substantiate the claims about mitochondrial function, the authors should ideally provide more direct functional data.\n\nTherefore, the manuscript requires Major Revision before it can be considered for publication. The authors must:\n1. Unequivocally clarify the experimental design for all groups during the treatment phase. If the design was flawed, the work may need to be repeated.\n2. Strengthen the mechanistic claims by adding direct functional assays for mitochondrial health and oxidative stress, or significantly tone down the conclusions to reflect the correlational nature of the current data.\n3. Revise the methods section to include precise details of all kits, reagents, and statistical tests.\n\n***\n\n## 第三阶段：结构化详细审稿意见 ##\n\n### 1. Title\n\n* Accuracy and Conciseness: The title is accurate and effectively summarizes the main findings.\n* Keyword Coverage: It includes all essential keywords (Resveratrol, PCOS, mitochondrial dysfunction, oxidative stress).\n* Journal Style Match: The style is appropriate for Frontiers in Endocrinology.\n\n### 2. Abstract\n\n* Structural Integrity: The abstract follows the standard Background, Methods, Results, Conclusion structure.\n* Element Coverage: It covers the key elements. However, the methods section in the abstract is ambiguous regarding the treatment protocol for the resveratrol group, mirroring the major flaw in the main text.\n* Core Result Logic: The results are presented logically.\n* Support for Conclusion: The conclusion that resveratrol improves PCOS by "enhancing mitochondrial biogenesis and function" is an overstatement. The data only show changes in the expression of regulatory proteins (SIRT1, PGC-1α) and an antioxidant enzyme (SOD2), not direct functional evidence of biogenesis or improved function (e.g., ATP production, mitochondrial DNA copy number). The conclusion should be moderated to state that resveratrol "may improve mitochondrial homeostasis by upregulating the expression of key regulatory proteins."\n\n### 3. Introduction\n\n* Research Background: The background is adequately presented. It establishes PCOS as a significant disorder and links it to mitochondrial dysfunction.\n* Scientific Question: The scientific question is clearly articulated: whether resveratrol can ameliorate PCOS by targeting ovarian mitochondrial dysfunction.\n* Research Purpose: The purpose of the study is well-defined.\n* Novelty Statement: The novelty is moderate, focusing on validating a known mechanism in the specific context of PCOS ovaries. This is acceptable, but the authors could state more explicitly that while resveratrol's effects on SIRT1/AMPK are known, its direct impact on ovarian mitochondrial regulators in a PCOS model has not been systematically shown.\n\n### 4. Methods\n\nThis section contains critical flaws that must be addressed.\n\n* Study Design Rationality:\n * Major Flaw: Section 2.4 is critically unclear and contradictory.\n * It first states: "The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole..." This appears to be a copy-paste error, as the control group should receive normal chow and vehicle. Please correct.\n * Most importantly, it states: "...the PCOS group was fed with continuous high-fat feed and given letrozole... and the resveratrol group was given resveratrol...". This implies the resveratrol group did NOT receive letrozole and high-fat diet during the treatment phase. If this is the case, the experiment is invalid, as the improvements could be due to the withdrawal of the disease-inducing agents. The authors must clarify that the resveratrol group was treated with letrozole + high-fat diet + resveratrol. If this was not the design, the experiments must be repeated.\n* Methodological Rigor:\n * Vague Reagent Descriptions: Terms like "NDA/RNA/Protein Kit", "BCA protein quantitative kit", "Western blot reagent" are insufficient. Please provide the full product name, manufacturer, and catalog number for all key reagents and kits to ensure reproducibility.\n * Insufficient Detail: The description of vaginal smear staining ("ultra-fast non-toxic modified Pasteur stain kit") is non-standard and vague. Specify the staining method (e.g., Diff-Quik, H&E).\n * Missing Information: Section 2.8 is missing from the manuscript. There is a jump from 2.7 to 2.9. Please check the numbering.\n* Statistical Analysis Appropriateness:\n * The description in 2.11 is too generic. "Two-way analysis of variance (ANOVA) was used to compare the means of multiple samples." This is likely incorrect for comparing the three endpoint groups (Control, PCOS, Res). A one-way ANOVA followed by a specific post-hoc test (e.g., Tukey's or Dunnett's test) should be used. For OGTT and ITT data, a two-way repeated measures ANOVA is appropriate. Please specify the exact statistical tests used for each experiment.\n * The use of a paired t-test for "pre and postoperative data" is unclear. Specify which data were analyzed this way (e.g., body weight before and after treatment within the same group).\n* Ethical Compliance: The ethics statement is present and appears adequate.\n\n### 5. Results\n\n* Data Integrity: The presented results seem internally consistent. However, their validity depends entirely on the clarification of the experimental design mentioned above.\n* Statistical Accuracy: The significance claims (P<0.05) cannot be fully evaluated without a proper description of the statistical methods.\n* Figure Quality: Figures are not included, but the descriptions are provided. Figure legends must be self-contained and provide enough detail to understand the experiment without referring to the main text, including the statistical test used and the sample size (n).\n* Logical Presentation: The flow of results from systemic metabolic changes to ovarian morphology and then to molecular mechanisms is logical. However, the conclusion in section 3.3 that resveratrol could "enhance mitochondrial biogenesis" is too strong. It enhances the expression of markers associated with biogenesis.\n\n### 6. Discussion\n\n* Result Interpretation: The interpretation is logical based on the presented data but suffers from two main issues:\n 1. It is predicated on a potentially flawed experimental design. If the design is invalid, the entire discussion is moot.\n 2. It overstates the conclusions. The authors repeatedly claim improved "mitochondrial function" and "biogenesis" without direct evidence. The discussion must be revised to reflect that they observed changes in regulatory pathways (SIRT1/PGC-1α) and antioxidant capacity markers (SOD2), which are suggestive of improved mitochondrial health, but not definitive proof of function.\n* Comparison with Existing Research: The discussion appropriately places the findings in the context of existing literature.\n* Novelty Discussion: The novelty is adequately discussed.\n* Limitations Analysis: A limitations section is absent. The authors must add one, explicitly stating:\n 1. The small sample size (n=6).\n 2. The major limitation that mitochondrial function and oxidative stress were not measured directly (e.g., via Seahorse analysis, ATP assays, ROS measurements, or assays for lipid peroxidation/protein carbonylation). The current data are correlational.\n* Future Outlook: The conclusion provides a reasonable future perspective.\n\n### 7. References\n\n* Timeliness and Relevance: The cited references appear relevant. Authors should ensure they have included the most recent key publications in the field.\n* Formatting: The format appears consistent, but a final check against the journal's guidelines is recommended.\n\n### 8. Figures & Tables\n\n* Necessity and Clarity: Based on the descriptions, the figures seem necessary to support the results.\n* Legend Integrity: As mentioned, figure legends must be comprehensive, detailing the groups, sample size (n=6/group), what the data represent (e.g., mean ± SEM), and the statistical tests performed. For example, the legend for Figure 1C should state "Data are mean ± SEM, n=6 per group. p < 0.05 vs. Control group, ##p < 0.01 vs. PCOS group, analyzed by two-way repeated measures ANOVA with post-hoc test."\n\n### 9. Point-by-Point Comments on the Manuscript Text\n\n Abstract, Sentence 4: "Resveratrol... is known for its potent antioxidant properties and its ability to improve mitochondrial function, but its specific effects and mechanisms in PCOS remain to be fully elucidated." - This is accurate.\n Abstract, Methods: The description of the groups is ambiguous. It should be clarified to: "...mice were randomly divided into a PCOS model group (letrozole + high-fat diet) and a resveratrol treatment group (letrozole + high-fat diet + resveratrol)."\n* Abstract, Conclusion: "...resveratrol may improve PCOS by enhancing mitochondrial biogenesis and function..." - Overstated. Change to "...by upregulating pathways associated with mitochondrial biogenesis and antioxidant defense...".\n* Section 2.1, Sentence 1: "This animal experiment was reviewed by the Experimental Animal Welfare Ethics Committee of the Experimental Animal Center of Global Medical University and complied with the Principles of Animal Protection, Animal Welfare and Ethics (IACUC)." - The name "Global Medical University" seems generic/fictional. Please provide the actual name of the institution.\n* Section 2.2: Provide catalog numbers and city/country for all suppliers (e.g., "Sigma-Aldrich, St. Louis, MO, USA"). "Keji Biological Company", "Biyuntian Biotechnology Institute", "Zhongshan Jinqiao", "Abbkine Company" are too vague.\n* Section 2.4, Sentence 2: "The mice in the control group were fed regular food and gavaged with normal saline daily." - Correct.\n* Section 2.4, Sentence 3: "The mice in the control group were given a high-fat diet and 1 mg/kg of letrozole..." - This is a direct contradiction to the previous sentence. This must be a typo and should refer to the PCOS modeling group, not the control group.\n* Section 2.4, Sentence 5: This sentence is the source of the critical design flaw. It needs to be rewritten to clarify the treatments for each of the three groups (Control, PCOS, PCOS+Resveratrol) during the 28-day treatment period.\n* Section 2.5, Sentence 3: "stain with an ultra-fast non-toxic modified Pasteur stain kit" - Replace with a standard method name, e.g., "stained with a Diff-Quik staining kit".\n* Section 2.6, Sentence 2: "After fasting for 14-16 h before the experiment..." - A 14-16h fast is long for mice and can induce metabolic stress. Is this standard for this model? A 6-8h fast is more common for OGTT. Please justify or reconsider.\n* Section 2.7, Sentence 2: A 4-6h fast for ITT is appropriate.\n* Section 2.9: The section number is incorrect (should be 2.8). Please renumber all subsequent sections.\n* Section 2.11, Sentence 3: "Two-way analysis of variance (ANOVA) was used to compare the means of multiple samples." - Incorrect for comparing three groups at one time point. Use one-way ANOVA.\n* Section 3.2, Sentence 4: "The serum testosterone (TP) and luteinizing hormone (LH) contents..." - TP is an abbreviation for total testosterone, which is fine, but it should be defined at first use.\n* Section 3.3, Sentence 3: "The immunohistochemical and immunofluorescence results of SIRT1 and PGC-1α (Figures 4A, B) revealed that..." - The methods section does not describe IHC or IF. This methodology must be added to Section 2.\n* Section 3.4, Sentence 2: "...the expressions of p-AMPK was significantly decreased..." - Grammatical error. Should be "...the expression of p-AMPK was..." or "...the levels of p-AMPK were...".\n* Section 4, Discussion, Sentence 5: "...we observed a significant downregulation of key regulators of mitochondrial health, SIRT1 and PGC-1α..." - Correct.\n* Section 4, Discussion, Sentence 7: "...activating mitochondrial biogenesis, leading to the formation of new, healthy mitochondria..." - This is an inference, not a direct observation. Rephrase to be more cautious, e.g., "...is a well-known mechanism for promoting mitochondrial biogenesis...".\n\n### 10. Consistency/Contradiction Assessment\n\n* Major Contradiction: The description of the experimental groups in Methods (Section 2.4) is contradictory and unclear, which creates a fundamental conflict with the interpretation of the results throughout the manuscript.\n* Methods vs. Results Mismatch: The results section (3.3) mentions immunohistochemistry and immunofluorescence, but these techniques are not described in the Methods section.\n* Introduction vs. Discussion Repetition: There is minimal overlap. The structure is generally good in this regard.\n\n### 11. Journal Recommendations\n\nGiven the critical flaw in the experimental design and the lack of direct functional data, this manuscript in its current form is not suitable for Frontiers in Endocrinology (2024 IF: 5.5). If the authors can address the methodological flaws but are unable to provide additional functional experiments, I recommend submitting to a journal with a focus on preclinical or descriptive findings.\n\nRecommended Journals (assuming no new functional data can be added):\n\n1. Experimental and Therapeutic Medicine\n * Impact Factor (2024): 2.7\n * CAS Partition: Medicine 4区\n * JCR Partition: Q4 (MEDICINE, RESEARCH & EXPERIMENTAL)\n * Review Cycle: ~4-6 weeks\n * Reason: Publishes sound preclinical studies, even if the mechanism is not deeply explored or the novelty is moderate. A good fit for the current data level after correction.\n\n2. Molecular Medicine Reports\n * Impact Factor (2024): 2.8\n * CAS Partition: Medicine 4区\n * JCR Partition: Q3 (MEDICINE, RESEARCH & EXPERIMENTAL)\n * Review Cycle: ~4-6 weeks\n * Reason: Similar to its sister journal above, it focuses on molecular mechanisms in disease models. The study fits its scope well.\n\n3. Journal of Ovarian Research\n * Impact Factor (2024): 3.3\n * CAS Partition: Medicine 3区\n * JCR Partition: Q2 (REPRODUCTIVE BIOLOGY)\n * Review Cycle: ~8-10 weeks\n * Reason: A specialized journal highly relevant to the topic. They publish animal model studies on PCOS. The bar for mechanistic depth might be slightly higher, but it is a viable option if the methods are rigorously corrected.\n\n4. Gynecological Endocrinology\n * Impact Factor (2024): 2.1\n * CAS Partition: Medicine 4区\n * JCR Partition: Q4 (OBSTETRICS & GYNECOLOGY)\n * Review Cycle: ~6-8 weeks\n * Reason: Focuses on the clinical and experimental aspects of gynecological endocrinology, making the topic a perfect fit.\n\n5. Biomedical Reports\n * Impact Factor (2024): 2.3\n * CAS Partition: Medicine 4区\n * JCR Partition: Q4 (MEDICINE, GENERAL & INTERNAL)\n * Review Cycle: ~4 weeks\n * Reason: A suitable outlet for case reports, and preclinical studies with clear, albeit not groundbreaking, findings.\n\n6. Endocrine, Metabolic & Immune Disorders - Drug Targets\n * Impact Factor (2024): 2.9\n * CAS Partition: Medicine 4区\n * JCR Partition: Q3 (PHARMACOLOGY & PHARMACY)\n * Review Cycle: ~8-12 weeks\n * Reason: Focuses on drug development for endocrine disorders, which aligns with the study's aim of evaluating resveratrol as a therapeutic agent.\n\n### 12. 用户判断\n\n您对上述审稿意见是否满意？是否基于当前意见进行文章修改？（请回答“是”或追加您的个性化问题，回答“是”进入修稿模式）。\n "}]